Agenus Inc. (NASDAQ:AGEN) Short Interest Update

Agenus Inc. (NASDAQ:AGEN) was the target of a significant growth in short interest in December. As of December 31st, there was short interest totaling 3,399,217 shares, a growth of 22.5% from the December 15th total of 2,774,043 shares. Approximately 10.6% of the company’s stock are short sold. Based on an average daily volume of 715,032 shares, the short-interest ratio is presently 4.8 days. Based on an average daily volume of 715,032 shares, the short-interest ratio is presently 4.8 days. Approximately 10.6% of the company’s stock are short sold.

Institutional Trading of Agenus

Several hedge funds have recently bought and sold shares of the company. Traynor Capital Management Inc. bought a new stake in shares of Agenus during the 3rd quarter worth about $50,000. Catalyst Funds Management Pty Ltd bought a new position in shares of Agenus in the second quarter valued at approximately $50,000. Squarepoint Ops LLC acquired a new position in shares of Agenus during the third quarter valued at approximately $54,000. Jump Financial LLC bought a new stake in Agenus during the second quarter worth approximately $55,000. Finally, Acadian Asset Management LLC acquired a new stake in Agenus in the first quarter worth approximately $58,000. 61.46% of the stock is currently owned by institutional investors.

Agenus Trading Up 0.9%

Shares of NASDAQ AGEN opened at $3.37 on Wednesday. Agenus has a 12-month low of $1.38 and a 12-month high of $7.34. The company has a market cap of $114.61 million, a price-to-earnings ratio of -1.58 and a beta of 1.58. The stock’s 50 day simple moving average is $3.86 and its 200 day simple moving average is $4.38.

Agenus (NASDAQ:AGEN) last issued its quarterly earnings data on Monday, November 10th. The biotechnology company reported $1.94 EPS for the quarter, missing analysts’ consensus estimates of $2.63 by ($0.69). The company had revenue of $30.24 million during the quarter, compared to analysts’ expectations of $80.39 million. As a group, equities analysts forecast that Agenus will post -12.55 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have commented on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Agenus in a report on Monday, December 29th. HC Wainwright restated a “buy” rating on shares of Agenus in a research note on Monday, October 20th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Agenus presently has a consensus rating of “Hold” and an average price target of $14.50.

Agenus Company Profile

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.